We are Aidence. Our purpose is to give lung cancer patients a fighting chance using AI.
We rally data scientists, software engineers, medical, regulatory, and business professionals.
We provide intelligent software that empowers healthcare and pharmaceutical professionals to deliver faster, more precise diagnostics and treatments.
Data is key to improve the prevention, management, and treatment of diseases.
Founded in Amsterdam by Mark-Jan Harte and Jeroen van Duffelen
Top algorithm in Kaggle challenge
CE Mark for Veye Lung Nodules
€10M series A investment
One of the first to renew CE mark under new EU Medical Device Regulation
Set-up a consortium to develop a Covid-19 solution, backed by the EU
NHS AI award (Phase 4) to improve lung cancer prognosis in the UK
€714k grant to expand lung nodule solution, in partnership with Erasmus MC and The Netherlands Cancer Institute
Collaboration with AstraZeneca to support early lung cancer diagnosis using AI
Preferred partner for the NHS England’s flagship lung cancer screening programme, the Targeted Lung Health Checks
Acquired by RadNet, US-based leading provider of diagnostic imaging services
Collaboration with Google Health to improve lung cancer screening with AI
Veye Lung Nodules mentioned in UK Parliament address on national lung cancer screening roll-out
Expand the suite of chest applications and augment the lung cancer pathway.
Our purpose is to improve people’s lives, from caregiver to patient.
We’re in a hyped industry, but we never exaggerate our capabilities.
We deliver what we promise, on time.
We encourage all stakeholders to speak openly and share their ideas.
We perfect one product before building the next and never stop improving.